SHERIDAN, WYOMING – July 1, 2025 – Protagonist Therapeutics has stepped into the fiercely competitive obesity treatment landscape by nominating PN-477, an innovative triple agonist therapy, aiming to deliver flexibility in dosing and a differentiated profile among next-generation anti-obesity drugs.
SHERIDAN, WYOMING – July 1, 2025 – Pfizer has announced the termination of its Phase II trial evaluating the investigational CD47-targeting fusion protein maplirpacept in diffuse large B-cell lymphoma (DLBCL), citing persistent recruitment difficulties that prevented the study from meeting enrollment targets.
SHERIDAN, WYOMING – July 1, 2025 – A late surge of acquisitions in June has reenergized pharmaceutical M&A activity, with six major deals announced that propelled first-half 2025 totals to 32 transactions across the industry. This burst of dealmaking, highlighted by BioNTech’s $1.25 billion acquisition of CureVac and Eli Lilly’s $1.3 billion buyout of Verve Therapeutics, has analysts optimistic that the sector’s cautious stance may finally be easing.
Resilient M&A Amid Regulatory Uncertainty
SHERIDAN, WYOMING – July 1, 2025 – A groundbreaking collaboration that delivered a custom-made CRISPR therapy to a nine-month-old patient with CPS1 deficiency has ignited optimism that ultrarare diseases could soon be addressed on a broader scale, thanks to advances in delivery systems, precision gene editing, and regulatory pathways.
SHERIDAN, WYOMING – July 1, 2025 – A wave of pivotal FDA decisions in June 2025 is reshaping key segments of the pharmaceutical landscape, with new approvals spanning respiratory syncytial virus (RSV) vaccines, advanced cancer treatments, and the first-ever antiviral for acute hepatitis C. These regulatory moves not only expand therapeutic options for patients but also set the stage for intensified competition in critical markets, underscoring strategic opportunities for companies across the biopharmaceutical sector.
SHERIDAN, WYOMING – June 16, 2025 – Roche has unveiled promising Phase III results for its immunotherapy Tecentriq® (atezolizumab) combined with lurbinectedin (Zepzelca®) in the treatment of extensive-stage small cell lung cancer (ES-SCLC), offering new hope for a patient population with few effective treatment options and historically poor survival outcomes.
SHERIDAN, WYOMING – June 12, 2025 – Genentech, a biotechnology powerhouse and subsidiary of Roche, has confirmed the layoff of 143 employees at its South San Francisco headquarters, marking the latest phase in a year-long operational reshaping. The company disclosed the reduction via a Worker Adjustment and Retraining Notification (WARN), with job terminations set to take effect on July 14.
SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling final overall survival data from its phase III INAVO120 study, showing that the Itovebi™ (inavolisib)-based regimen reduces the risk of death by more than 30% in patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The findings were presented at the 2025 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.
First PI3K Inhibitor to Prolong Survival in This Breast Cancer Subtype
SHERIDAN, WYOMING – June 1, 2025 – Roche has announced compelling new data from its ongoing FENopta open-label extension study, confirming that its investigational therapy fenebrutinib continues to provide sustained disease suppression in patients with relapsing multiple sclerosis (RMS) for up to two years.
SHERIDAN, WYOMING – May 27, 2025 – Roche has received a significant endorsement from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP), which issued a positive opinion for Itovebi™ (inavolisib) in combination with palbociclib and fulvestrant. This recommendation positions Roche to offer a first-line treatment solution for adult patients with PIK3CA-mutated, ER-positive, HER2-negative, locally advanced or metastatic breast cancer—an area with limited current treatment options.